AbSci (ABSI)
NASDAQ:ABSI
ABSI Stock Chart & Stats
$2.98
$0.12(3.91%)
At close: 4:00 PM EST
$2.98
$0.12(3.91%)
Day’s Range― - ―
52-Week Range$2.24 - $5.23
Previous CloseN/A
Volume51.94M
Average Volume (3M)4.03M
Market Cap
$456.00M
Enterprise Value$441.28M
Total Cash (Recent Filing)$144.29M
Total Debt (Recent Filing)$5.30M
Price to Earnings (P/E)―
Beta2.13
Next Earnings
May 19, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding153,021,260
10 Day Avg. Volume3,405,149
30 Day Avg. Volume4,033,709
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)2.52
Price to Sales (P/S)170.48
P/FCF Ratio-5.08
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue157.60
Enterprise Value/Gross Profit-11.98
Enterprise Value/Ebitda-3.91
Forecast
1Y Price Target
$7.64Price Target Upside156.38% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.78
Revenue Forecast (FY)$9.02M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy ReadoutAnalyst notes an interim multiple‑dose proof‑of‑concept readout could provide the first clear clinical efficacy signal and benchmark hair‑count improvements versus existing treatments, creating a major inflection point for the stock.
Novel Mechanism Of ActionAnalyst highlights ABS‑201's prolactin‑blocking mechanism as a targeted alternative to vasodilator therapies that could deliver more durable hair regrowth and improve payer recognition if clinical efficacy is confirmed.
Platform And Commercialization StrategyAnalyst notes the Origin‑1 AI platform can accelerate identification of high‑affinity leads while an asset‑based out‑licensing strategy combined with reported cash resources could enhance value capture and fund further development.
Bears Say
Early Clinical RiskAnalyst applies a conservative probability of success because the program remains in early clinical development, making valuation highly sensitive to initial patient readouts and safety findings.
Financial PerformanceQuarterly results showed revenue below consensus and a wider loss per share than expected, which could increase near‑term financial pressure and heighten the risk of future dilution.
Market Adoption And Investor AwarenessLimited investor awareness of prolactin targeting and survey evidence that many patients are satisfied with current options could constrain early uptake and sustain investor skepticism until robust human efficacy data are available.
AbSci News
ABSI FAQ
What was AbSci’s price range in the past 12 months?
AbSci lowest stock price was $2.24 and its highest was $5.23 in the past 12 months.
What is AbSci’s market cap?
AbSci’s market cap is $456.00M.
When is AbSci’s upcoming earnings report date?
AbSci’s upcoming earnings report date is May 19, 2026 which is in 35 days.
How were AbSci’s earnings last quarter?
AbSci released its earnings results on Mar 24, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.178 by -$0.022.
Is AbSci overvalued?
According to Wall Street analysts AbSci’s price is currently Undervalued.
Does AbSci pay dividends?
AbSci does not currently pay dividends.
What is AbSci’s EPS estimate?
AbSci’s EPS estimate is -0.19.
How many shares outstanding does AbSci have?
AbSci has 153,021,260 shares outstanding.
What happened to AbSci’s price movement after its last earnings report?
AbSci reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.178. Following the earnings report the stock price went down -2.99%.
Which hedge fund is a major shareholder of AbSci?
Currently, no hedge funds are holding shares in ABSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AbSci Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.64 (156.38% Upside)
$7.64 (156.38% Upside)
Blogger Sentiment
Neutral
ABSI Sentiment 50%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $96.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
21.38%
12-Months-Change
Fundamentals
Return on Equity
-59.68%
Trailing 12-Months
Asset Growth
1.26%
Trailing 12-Months
Company Description
AbSci
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
ABSI Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial progress and multiple near-term catalysts: first-in-human dosing for ABS-201 with favorable emerging safety/PK, an expanded indication into endometriosis with a planned Phase 2, published platform validation for de novo antibody design, strong survey-based commercial interest, and a stated cash runway into 2028. Counterbalancing these positives are modest current revenue, increased R&D spend (+37.5% YoY for the quarter), a sequential cash decline (-5.4%), early-stage clinical evidence with limited exposure, and competitive/regulatory uncertainties. On balance, the momentum on clinical advancement, platform differentiation, and market interest outweigh the present financial burn and early-stage risks.View all ABSI earnings summariesABSI Stock 12 Month Forecast
Average Price Target
$7.64
▲(156.38% Upside)
Technical Analysis
Autolus Therapeutics
―
―
ADC Therapeutics
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Ownership Overview
6.81% Insiders
20.72% Mutual Funds
27.57% Other Institutional Investors
24.81% Public Companies and
Individual Investors